MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma
Jia Ruan(Cornell University), Peter W. Martin(Cornell University), Kami J. Maddocks(The Ohio State University), Bijal Shah(Boston College), Michael Sigouros(Cornell University), Gui Zhen Chen(University of Washington), John N. Allan(Cornell University), Bhavneet Bhinder(Cornell University), Jenny Xiang(Cornell University), John P. Leonard(New York University), Caitlin Gribbin(Cornell University), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Olivier Elemento(Cornell University), Wayne Tam(Cornell University), Brittany Hobbie(Cornell University), Sarah C. Rutherford(NewYork–Presbyterian Hospital), Zhengming Chen(Cornell University), T. Sahni(Cornell University), Selina Chen‐Kiang(NewYork–Presbyterian Hospital), Melinda Harbhajan(Cornell University), Giorgio Inghirami(Cornell University)
Cited by 3
Related Papers
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
|Nature Cell Biology|2015|2.7k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Ferroptosis is an autophagic cell death process
|Cell Research|2016|1.9k
Double-stranded DNA in exosomes: a novel biomarker in cancer detection
|Cell Research|2014|1.6k